JUBLIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUBLIA (JUBLIA).
Efinaconazole inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Hepatic metabolism via CYP3A4 and CYP2C19, with minor contribution from CYP2C9 and CYP2C8. |
| Excretion | Primarily fecal (unchanged drug and metabolites); renal elimination is negligible (<1% as unchanged drug in urine). |
| Half-life | Terminal elimination half-life is approximately 72 hours (range 48–96 hours) after topical application, supporting once-weekly dosing. |
| Protein binding | Efinaconazole is >99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into tissues, including nails. |
| Bioavailability | Bioavailability after topical application to nails is negligible systemically (plasma concentrations are low, <0.5 ng/mL). No oral formulation exists. |
| Onset of Action | Onset of clinical improvement (visible nail growth) typically occurs after 4–8 weeks of weekly application; complete cure requires regrowth of healthy nail (48–52 weeks). |
| Duration of Action | Drug persists at the site of action for at least 7 days after a single application, enabling weekly dosing. Therapeutic effect continues throughout treatment course until nail replacement is complete. |
Apply a thin layer of tavaborole 5% solution to the affected toenails once daily for 48 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required in patients with renal impairment. Drug not significantly eliminated renally. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy have not been established in pediatric patients below 18 years of age; thus, not recommended. |
| Geriatric use | No specific dose adjustments are recommended for elderly patients, but consider potential for concurrent comorbidities and medication use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JUBLIA (JUBLIA).
| Breastfeeding | It is not known whether efinaconazole is excreted in human milk. Following topical application, systemic absorption is limited (<1% of dose). The M/P ratio has not been determined. Due to low systemic exposure, the amount likely transferred to the infant via breast milk is negligible. Caution should be exercised when JUBLIA is administered to a nursing woman. |
| Teratogenic Risk | JUBLIA (efinaconazole) is a topical triazole antifungal. Based on animal studies and limited human data, systemic absorption is minimal (<1%) following topical application. In animal reproduction studies, no evidence of fetal harm was observed at systemic exposures up to 116 times the human exposure at the maximum recommended human dose (MRHD). However, there are no adequate and well-controlled studies in pregnant women. Because systemic absorption is negligible, the risk of teratogenicity is considered low, but as a precaution, use during pregnancy only if clearly needed. No specific fetal risks have been identified for any trimester. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to efinaconazole or any component of the formulation"]
| Precautions | ["Local irritation (burning, stinging, itching) at application site","Avoid contact with eyes and mucous membranes","Not for ophthalmic, oral, or intravaginal use"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care. Because systemic absorption is minimal, maternal serum levels are not clinically significant. No fetal monitoring is indicated. |
| Fertility Effects | No fertility studies have been conducted specifically with efinaconazole. Animal studies with other triazole antifungals have shown some effects on fertility at high systemic doses, but given the negligible systemic absorption of topical efinaconazole, no significant impact on human fertility is expected. |